AVRO News and Press, AVROBIO Inc. From 05/17/22

New early data show key visual motor integration, visual perception and motor coordination measures impacted by cystinosis stabilized or improved post gene therapy Systemic reach of AVR-RD-04 observed across multiple other measures All five dosed patients remain off or...

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced members of its senior management team will be presenting virtually at the H.C. Wainwright Global Investment Conferenc...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

AVROBIO press release (NASDAQ:AVRO): Q1 GAAP EPS of -$0.68 misses by $0.11. As of March 31, 2022, AVROBIO had $161.7 million in cash and cash equivalents, as compared to $189.6 million in cash and cash equivalents as of December 31, 2021. Shares +1.97% PM. For further details see: AVROB...

Phase 1/2 collaborator-sponsored 1 clinical trial in cystinosis fully enrolled New interim cystinosis clinical data to be presented at the 25 th annual meeting of the American Society of Gene and Cell Therapy (ASGCT) Multiple regulatory interactions planned...

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that new data from its ongoing, collaborator-sponsored 1 Phase 1/2 clinical trial in cystinosis will be presented...

AVROBIO Inc. (NASDAQ:AVRO) traded today at a new 52-week high of $53.19. Approximately 18.2 million shares have changed hands today, as compared to an average 30-day volume of 355,000 shares. In the past 52 weeks, AVROBIO Inc. share prices are bracketed by a current low of $1.17 and a hi...

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the 21 st Annual Needham Virtual Healthcare Conference...

AVROBIO press release (NASDAQ:AVRO): Q4 GAAP EPS of -$0.65 beats by $0.10. As of Dec. 31, 2021, AVROBIO had $189.6M in cash and cash equivalents, as compared to $259.7M in cash and cash equivalents as of Dec. 31, 2020. For further details see: AVROBIO GAAP EPS of -$0.65 beats by $0.10 ...

Provided interim data at WORLDSymposium™ 2022 that showed sustained engraftment across first three patients 1 + year post-gene therapy in Phase 1/2 clinical trial i for cystinosis; all remain off oral cysteamine to date Interim clinical data update of AVR-RD...